A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors
NCT07911579, Phase 1, Phase 2, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors | ClinicalTrials.gov |
| NCT number | NCT07911579 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1, Phase 2 | ClinicalTrials.gov |
| Enrollment | 154 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | ClinicalTrials.gov |
| Conditions | Advanced Solid Tumors | ClinicalTrials.gov |
| Interventions | SYH2051, Irinotecan Hydrochloride Liposome. | ClinicalTrials.gov |
| First posted | 2026-11-03 | ClinicalTrials.gov |
| Last updated | 2026-11-03 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | DLT | From Day 1 to Day 28 | ClinicalTrials.gov | |
| Primary | Frequency and severity of AE | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Primary | Maximal tolerable dose (MTD) | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Primary | Recommended phase 2 dose (RP2D) | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Primary | ORR | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Secondary | Cmax | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Secondary | AUCss, | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Secondary | ORR | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Secondary | PFS | From Day 1 to 12 months. | ClinicalTrials.gov | |
| Secondary | OS | From Day 1 to 18 months. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)